Although both treatments led to a drop in the relative proportion of TCF1+ T cells, the absolute number of tumor-specific, stem-like cells expressing PD-1+ and TCF1+ increased, with αCD45-Cyt therapy eliciting a sixfold higher count of stem-like cells in the TDLNs over untreated mice (Fig. 5h,i). The gene discussed is PDCD1; the disease is neoplasm.